Flamini R, Mattivi F, De Rosso M, Arapitsas P, Bavaresco L
Discussion Understanding the potential impacts of the increasingly prescribed GLP-1 receptor agonist semaglutide in the clinics is essential to guarantee its safety, particularly as growing evidence highlights its broad physiological effects
DSIP From R750 Quick links Protocols Sleep Optimisation & Insomnia Treatment Dosage: 100300 mcg before bed (subcutaneous injection) Cycle: Continuous use for 46 weeks, followed by a 2-week break Administration: Best taken 3060 minutes before bedtime Stacking: With Melatonin for circadian rhythm regulation With Semax or Selank for stress and anxiety control With CJC-1295 & Ipamorelin for GH release and deep sleep improvement Expected Benefits: Faster sleep onset and reduced sleep latency Increased deep delta wave sleep (slow-wave sleep) No grogginess or next-day drowsiness 2
Future research should focus on high-quality RCTs to clarify optimal populations, doses, and durations for BCAA application, and explore synergistic effects of BCAAs with other therapeutic interventions
Development of GLP-1MK-801 To safely harness the weight-lowering properties of NMDA receptor antagonism, we developed a targeting approach based on the hypothesis that conjugation of MK-801 to a GLP-1 analogue through a chemically cleavable disulfide linker would enhance the therapeutic potential of NMDA receptor antagonism in appetite-regulating brain regions enriched for GLP-1 receptors, while mitigating the adverse effects related to the non-restricted actions of MK-801
Quick Research Math Example Here is the cleanest way to think about the math
